AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for ...

Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $170 and keeps a Buy rating on the shares following a transfer of ...

In its upcoming report, AbbVie (ABBV) is predicted by Wall Street analysts to post quarterly earnings of $2.92 per share, reflecting a decline of 1% compared to the same period last year. Revenues are ...

On Thursday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $189.65 which represents a slight increase of $1.77 or 0.94% from the prior close of $187.88. The stock opened at $188.43 ...

AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Argent Capital Management LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 96.3% in the 3rd quarter, ...

American Institute for Advanced Investment Management LLP boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric ...